FTC Commissioner Urges Generic Firms To Shun Reverse Payment Deals
Executive Summary
The generic industry should refrain from entering into settlement agreements with brand companies that involve payments to keep generics off the market, Federal Trade Commissioner Jon Leibowitz said at the Generic Pharmaceutical Association's Annual Policy Conference in Washington, D.C. Sept. 19
You may also be interested in...
Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix
A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments
Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix
A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments
Brand Prices Increase More When Authorized Generics Launch – GPhA Study
A study commissioned by the Generic Pharmaceutical Association found that brand prices increased more when an "authorized" generic is launched during the first generic's 180-day exclusivity period